// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Bad News or Life Altering Diagnoses? Neurology Residents’ Attitudes towards Disclosing Diagnoses (P1.048)

Janis Miyasaki - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A Prospective Longitudinal Study of Antipsychotic Safety in Children with Tourette Syndrome (P6.016)

Tamara Pringsheim - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Tolerability and Retention to Fingolimod in RRMS Patients who Switched from other Oral DMTs (P2.393)

Yves Lapierre - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fingolimod

Reliability of automated software to assign e-ASPECTS to CT scans for acute ischemic changes (S8.006)

Lisa C Hoyte - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Finger-to-nose test findings in Alzheimer’s disease (P6.071)

David Bergeron - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Inhibitor Development in Previously Untreated Patients with Severe Haemophilia a Treated with Human‐CL RHFVIII, a New Generation Recombinant FVIII of Human Origin

E. J. Neufeld - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

rFVIII

Health related quality of life questionnaires in individuals with hemophilia: a systematic review of their measurement properties

P. Limperg - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Test‐Retest Reliability Analysis of The Patient Reported Outcomes Burdens and Experiences (PROBE) Study

C. Chai-Adisaksopha - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Assessment of Therapeutic Relationship in Haemophilia Care

E. Mccabe - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

The Development of the World Bleeding Disorders Registry Pilot Phase

J. O'Hara - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Advantages of Point of Care Splinting In Pediatric Patients With Hemophilia

L. De Marchi - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Nonacog Beta Pegol For The Prophylactic Treatment of Children With Haemophilia B: Interim Results From The Paradigm™ 5 Clinical Trial

M. Carcao - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Addressing Common Problems in Hemophilia Care Across Diverse Global Healthcare Settings

M. E. Mancuso - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

“I JUST WANT MY LIFE BACK”: PHYSICAL FUNCTION AND FATIGUE ARE CRITICAL TARGETS FOR IMPROVING PARTICIPATION AND HRQL IN RHEUMATOID ARTHRITIS

S.J. Bartlett - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

ABATACEPT SHOWS BETTER SUSTAINABILITY THAN TNF INHIBITORS WHEN USED FOLLOWING INITIAL BIOLOGIC DMARD FAILURE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: 8 YEARS OF REAL-WORLD OBSERVATIONS FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY

D. Choquette - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Abatacept

ADALIMUMAB IN NON-INFECTIOUS UVEITIS – EFFICACY ACROSS DIFFERENT ETIOLOGIES IN THE VISUAL I AND VISUAL II TRIALS

P.T. Merrill - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

N/A

Adalimumab

CLINICAL CHARACTERISTICS OF SPONDYLARTHRITIS (SPA) WITH AND WITHOUT PERIPHERAL ENTHESITIS – DATA FROM THE DESIR COHORT

V. Nadon - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

N/A

EARLY ONSET OF EFFICACY WITH APREMILAST MONOTHERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: A PHASE 3B, RANDOMIZED, CONTROLLED TRIAL

P. Nash - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Dermatology

N/A

Apremilast

INCREASED PREVALENCE OF EXTRA-ARTICULAR MANIFESTATIONS AMONG INDIVIDUALS WITH ANKYLOSING SPONDYLITIS IN CANADA: RESULTS FROM THE RHUMADATA® MULTICENTRE REGISTRY

S. Szabo - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

N/A

LOW RATES OF MAJOR ADVERSE CARDIAC EVENTS, MALIGNANCIES, AND SERIOUS INFECTIONS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS TREATED WITH APREMILAST FOR ≥156 WEEKS: POOLED ANALYSIS FROM THE ESTEEM AND PALACE 1-3 PHASE 3 TRIALS

A. Kavanaugh - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Apremilast

Copyright © 2026. QuantiNova All rights reserved